Estimates Revisions Immutep Limited Nasdaq
Stocks
IMMP
US45257L1089
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
21:00:00 22/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.2831 USD | -2.81% |
|
-14.29% | -90.10% |
| 09-17 | Immutep refocuses efti development on head and neck cancer and soft tissue sarcoma | FI |
| 09-15 | Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Immutep Limited(IMM)
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
- Stock Market
- Stocks
- IMM Stock
- IMMP Stock
- Consensus Immutep Limited
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
